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ABSTRACT: 
MicroRNAs (miRNAs) are small, subtypes of RNA that are 22-25 nucleotides in length that regulate the gene 
expression by targeting homologous sequences in messenger RNA (mRNA). Their unusual expressions have been 
observed in various types of cancers. In this paper we first briefly outline of multiple pairwise alignment of pri-
miRNA-125 of three organisms and secondary structure. We then discuss in detail on binding sites of miRNA-125 
with different target genes to known the binding energy using computational tool. Finally, we discuss on mechanism 
of miRNA-125 over-expression causes different types of leukemia due to abnormal expression of gene present on 
chromosome 21. Thus we have reported that one of the major causes of leukemia is abnormal expression of miRNA-
125. 
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[I] INTRODUCTION 
MicroRNAs (miRNAs) are small non-coding, 
single stranded RNA molecules with 22-25 
nucleotides in size, that regulate specific target 
mRNA by complementary seed region in the 
3'untranslated region (UTR) by cleaving or 
repressing the transition. [4, 1]. miRNA have 
various functions in gene regulation, including 
proliferation, differentiation, and apoptosis [38]. 
Depending up on cellular contents miRNA-125 
undergo proliferation and apoptosis in breast 
cancer, [53, 55, 22, 52, 27,] prostate, [58, 36, 12, 
57, 60, 29] hematopoietic stem cells, [21] 
leukemia [65] and in lung cancer [64]. miR-125b 
expression regulates cell proliferation by 
inhibiting osteoblastic differentiation [46]. 
High expression of miR-125b in mouse activates 
the actin distribution and the shape of fibroblast 
[24]. miR-125a-5p expression in liver cell down-
regulate the HBV S gene thus reducing the 
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amount of secreted HBsAg [50]. In rats over-
expression of miR-125a regulate hyperglycemic 
phenotype in adipose and liver tissue [26]. In 
human neuroblastoma and lung fibroblast cells 
expression of miR-125b target p53 and induce 
apoptosis due to stress [35]. Recent studies have 
shown that miR-125 expression in hippocampal 
neurons [13], human-astroglial (HAG) cells [49] 
and glioma stem cell [62, 56]. 
In this study, we focused on miRNA-125, its 
regulatory function and analyzed the positive and 
negative regulation in different types of 
cells/tissues by using literature studies. We have 
analyzed the pairwise alignment of pre-miR-125 
in human, mouse and rats. Further we find the 
binding energy of miRNA- target gene. Finally, 
we are interested in finding the mechanism 
network due to expression of miR-125 in 
different types of cells. Altogether the reports 
explain that miR-125 act as an oncogene and 
cause leukemia. 
 
[II] METHODS 
2.1 Collection of data 
Initially, we started with downloading the papers 
that are available on pubmed, science direct, etc., 
among the paper retrieves we selected those 
papers that are mainly concentrating on miRNA-
125 in the title of the papers. We studied those 
papers and started collecting the information of 
expression of miRNA-125, cell type, and miRNA 
target gene. During our studies on miRNA-125, 
we collected some of the information on the 
available papers then we started with tabulating 
all the observations and put it into consolidated 
into a table as shown in Table 1. That contains 
the information heading as miRNA names in 
which species studies involved, types of cell 
study, target gene, expression of miRNA and its 
functions. We then analyzed regulation of 
miRNA and classified the tabulation into positive 
and negative regulation of miRNA. We came 
across many data which have been explained in 
result. 
2.2 Analysis of sequences 
We collected all the sequences of miRNA-125 in 
pre-mature and mature sequence from miRBase 
(release 18) for sequence alignment studies. On 
the other hand, the gene that is target for miRNA-
125, those target gene mRNA nucleotides are 
collected from the database of National Centre of 
Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov). We used open 
source MiRanda 3.3 version software to predict 
miRNA- target sequence alignment 
(http://www.microrna.org) and also to find 
binding energy. RNA folding of mir-125 is 
retrieved by Geneious software.  
 
[III] RESULT AND DISCUSSION 
3.1 Identification of miRNA-125 
In human miR-125a cluster present on 
chromosome (chr) 19 which contain three genes 
of miRNA: miR-125a, miR-let-7e and miR-99b. 
miR-125b cluster present on chr 21 which contain 
three genes of miRNA: miR-125b, miR-let-7c 
and miR-99a. In mouse miR-125a and miR-125b 
cluster are sited in chr 17 and 16 [23]. The pre-
mature miRNA-125 sequences of human, mouse 
and rat are collected from miRBase-release 18 
[33]. We started with analyzing all sequences of 
miRNA-125a/b of the three organisms by using 
Geneious 5.6.4. 
We performed Global Multiple Sequence 
Alignment (MSA) with cost matrix: 65% 
similarity (5.0/-4.0), gap open penalty 12, gap 
extension penalty 3, for the pre-mir-125 between 
Homo sapiens (human), Mus musculus (mouse) 
and Rattus norvegicus (rat). The alignment is 
shown in Figure 1 (A, B, C) and is highly 
conserved with transition mutation result in 
conversation of A ->G and U ->C in all the three 
sequences. RNA folding of miR-125a/b is shown 
in Figure 2. 
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Fig: 1A. multiple Pairwise alignment of pre-mir-125a with Identical Sites: 80 (94.1%), Pairwise % Identity: 96.8%. 
1B. multiple Pairwise alignment of pre-mir-125b-1 with Identical Sites: 86 (98.9%), pairwise % Identity: 99.2%. 
1C. multiple Pairwise alignment of pre-mir-125b-2 with Identical Sites: 85 (96.6%), Pairwise % Identity: 97.8%. 
hsa-miR-125a               
mmu-miR-125a       
rn-miR-125a          
 
hsa-miR-125b-1      
                   
mmu-miR-125b-1               
rno-miR-125b-1            
hsa-miR-125b-2      
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mmu-miR-125b-2      
rno-miR-125b-2         
Fig: 2. Secondary structure of the novel miRNA-125. Comparison of secondary structures of miR-125a/b between Homo sapiens 
(hsa), Mus musculus (mmu) and Rattus norvegicus (rno) that are retrieved by RNA fold have included in the Geneious software 
package. 
3.2 Database of miRNA-125 
For this study, first we collected approximately 40 published papers from various schools of 
thoughts (Table 1) and understood the mechanism and role played by the miRNA in particular 
cell/ tissues, which has been collated in Table 1.  
Organisms miRNA Name 
Oncogenes 
target  
(genes) 
Cell types Type of Interactions Effect of miRNA Refer
ences 
Mouse miR-125b TEF Fibroblasts actin distribution and the shape of fibroblast Over-expression 24 
Human miR-125b BMPR1B breast cancer increased breast cancer risk downregulation 53 
Human miR-125b c-raf-1 human breast cancer Decreases the levels of oncogene proteins and stimulates cell death. expression 27 
Human miR-125b Bak1 prostate cancer cells promotes proliferation Over-expression 58 
Human, 
Mice miR-125b 
Bak1, 
Ppp1ca neuroblastoma cells pro-apoptosis expression 34 
Human miR-125b 
Tp53, 
Tp53inp1, 
Cdc25c, 
Ppp2ca 
neuroblastoma cells pro-apoptosis expression 34 
Mice miR-125b Itch, Puma neuroblastoma cells anti-apoptosis expression 34 
Human miR-125a/b ERBB2/ ERBB3 breast cancer suppresses cell proliferation Over-expression 55 
Human miR-125b 
KLF13, 
CXCL11, 
FOXA1 
oral squamous cell 
carcinoma (OSCC) 
cause cancer because loss of chr in 
11q and 21 which regulate the 
miR125, miR-125 is downregulated 
Down-regulation 25 
Human miR-125b 
KLF13, 
CXCL11, 
FOXA1 
oral squamous cell 
carcinoma (OSCC) reduced cell proliferation 
increase the 
expression 25 
Human miR-125b-2 
lin-28, lin-
41 Prostate Cancer 
reduced proliferation of 
differentiated cells. 
depletion or 
down-regulation 36 
Human miR-125a-5p EGFR lung cancer cells 
migration and invasion of lung 
cancer cells Down-regulation 60 
Human miR-125a-5p 
IL16, 
CCL21, 
CCL4, 
IGF-2 
non-small cell lung cancer 
(NSCLC) 
enhance cell migration and invasion 
in cancer cell Down-regulation 29 
Mouse miR-125b-2 - 
hematopoietic progenitor 
cell 
leukemia’s with the structural 
ETV6/RUNX1 abnormality Over-expression 19 
Human miR-125b-2 - lymphoid progenitors 
survival and growth of lymphoid 
progenitors(suppressing apoptosis 
and caspase 3 activation) 
expression 19 
Human miR-125b-2 - leukemic cells ETV6/RUNX1 ALL expression 19 
Human miR-125b - ETV6/RUNX1 leukemia partial protection from apoptosis 
repression after 
treating with 
drug 
19 
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Human miR-125a-5p 
HBV S 
gene (HBV 
3037–3065) 
liver  (hepatic cells) 
down-regulate the expression of 
HBV S gene thus reducing the 
amount of secreted HBsAg. 
expression 50 
Mouse miR-125b IGF-II myoblast myoblast differentiation and muscle 
regeneration Down-regulation 18 
Mouse miR-125b IGF-II skeletal muscle skeletal muscle regeneration Down-regulation 18 
Human miR-125a p53 
 
reduces p53 protein expression expression 66 
Human miR-125b BLIMP-1 germinal centers(GC)  phase of B cell 
inhibits B cell differentiation and 
enhances cell death of myeloma cells Over-expression 23 
Mouse miR-125b IRF-4 germinal centers(GC)  phase of B cell 
inhibits B cell differentiation and 
enhances cell death of myeloma cells Over-expression 23 
Mice miR-125a Bak1 hematopoietic stem cells (HSC) 
reduction of apoptosis in immature 
hematopoietic progenitors cells expression 21 
Mice miR-125b - fetal liver cells increase in WBCs associated with a 
macrocytic anemia Over-expression 6 
Mice miR-125b - fetal liver cells B-cell / T-cell acute lymphoblastic leukemia Over-expression 6 
Mice miR-125b - fetal liver cells 
induce primary lymphoid or myeloid 
leukemia  by BCR-ABL fusion 
protein 
Over-expression 6 
Human miR-125a truncated TrkC 
medulloblastoma 
carcinogenesis 
promote medulloblastoma cell 
growth arrest and apoptosis Down-regulation 16 
Human miR-125a truncated TrkC 
medulloblastoma 
carcinogenesis treatment that inhibits tumor growth 
Up-regulated by 
RA (All-trans-
retinoic acid) 
16 
Rats(Goto
-Kakizaki 
[GK] 
spontaneo
usly 
diabetic 
miR-125a 
Slc35c2, 
Umps, 
Ptges2, 
Ppap2c, 
Sult1a1 
adipose  and liver tissue hyperglycemic phenotype Over-expression 26 
 
Human miR-125a HuR breast cancer 
inhibited cell growth via suppression 
of cell proliferation and promotion 
of apoptosis and also inhibit cell 
migration 
Over-expression 22 
Human miR-125b p53 human neuroblastoma cells 
and lung fibroblast cells represses apoptosis increase 35 
Human miR-125b p53 lung fibroblast cells induces apoptosis Down-regulation 35 
Human miR-125b BAK1 human prostate carcinoma decrease the apoptosis increase the 
expression 12 
Human miR-125b Bak1 Ovarian Cancer decreased cisplatin-induced cyto   toxicity Over-expression 32 
Human miR-125b Bak1 Ovarian Cancer increased cisplatin sensitivity in 
cisplatin-resistant cells Down-regulation 32 
Mouse miR-125b ErbB2 mesenchymal stem cells attenuated in osteoblastic-differentiated expression 46 
Mice miR-125b p53, puma, bak1 prostate cancer 
promotes growth of prostatic 
xenograft tumors Over-expression 57 
Human miR-125b STAT3 osteosarcoma tissue 
suppressed proliferation and 
migration of cell decreased tumor 
formation 
Over-expression 41 
Human miR-125b STAT3 osteosarcoma tissue proliferation and migration of cell 
result in cancer Down-regulation 41 
Human miR-125b CBFβ malignant myeloid cell Myeloid Cell proliferation and promoting leukemogenesis expression 39 
Human miR-125b CBFβ malignant myeloid cell promote myeloid differentiation Down-regulation 39 
Human miR-125b-2 
DICER1 
ST18 
HSPCs (hematopoietic 
stem and progenitor cells) 
increase the proliferation and 
enhances their ability to self-renew 
(presumed cells of origin for DS-
AMKL/TL) (Down syndrome )-
(acute megakaryoblastic leukemia) 
Over-expression 31 
Human miR-125b-2 DICER1 
HSPCs (hematopoietic 
stem and progenitor cells) 
DS-AMKL (Down syndrome )-
(acute megakaryoblastic leukemia) 
highly over-
expression 31 
Human miR-125b DICER1 HSPCs (hematopoietic 
stem and progenitor cells) 
inhibits DS megakaryocytic 
leukemia cell growth. Down-regulation 31 
Mouse miR-125b ST18, DICER1 hematopoietic cells 
proproliferative effect on 
hematopoietic progenitor cells Over-expression 31 
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Human miR-125b MUC1 breast cancer cell promote DNA damage and increase the apoptotic Over-expression 52 
Human miR-125b MUC1 breast cancer cell result in breast cancer Down-regulation 52 
Human miR-125b MLF2 
myelodysplastic 
syndromes (MDS) and 
acute myeloid  leukemia 
(AML) patients 
the arrest of maturation  by  
morphology and reduced expression 
of CD14 in  monocytic cells 
Up-regulation 
(from 6- to 90-
fold) 
7 
Human miR-125b MCL1 
myelodysplastic 
syndromes (MDS) and 
acute myeloid  leukemia 
(AML) patients 
block late stages of differentiation. Up-regulation 7 
Human miR-125b notch1, p53 haiey haiey disease (HHD) keratinocytes 
keratinocytes proliferation and 
differentiation Over-expression 43 
Human miR-125b NR2A Hippocampal neurons long thin protrusions and altered 
synaptic function Over-expression 13 
Human miR-125a ARID3B ovarian cancer 
represses the mesenchymal 
phenotype and prevent cancer or 
maintaining an epithelial 
morphology or induces a 
mesenchymal-to-epithelial transition. 
Over-expression 11 
Human miR-125a ARID3B ovarian cancer mesenchymal morphologies or behaviors in cancer repression 11 
Human miR-125a-5p - 
lung squamous cell 
carcinoma (SCC), in lung SCC Up-regulation 64 
Human miR-125b BAK1 
pediatric acute 
promyelocytic leukemia 
(APL) 
reduced apoptosis and enhanced 
proliferation of leukemic cells and 
further induce oncogenesis 
Over-expression 65 
Human miR-125b NF-кB human-astroglial (HAG) 
cells 
increase the neurological disorders 
including Alzheimer's disease (AD) 
due iron and aluminum-sulfate metal 
(reactive oxygen species) 
Up-regulation 49 
Human miR-125b CDK6, CDC25A Glioma stem cell induced proliferation Down-regulation 56 
Human miR-125b CDK6, CDC25A Glioma stem cell proliferation defect Over-expression 56 
Human miR-125b CDKN2A normal human 
astrocytes(NHA) IL-6 induce proliferation Up-regulation 48 
Human miR-125b Bmf human glioma cell 
proliferation and inhibits all-trans-
retinoic acid (ATRA)-induced cell 
apoptosis(inhibit apoptosis) 
Over-expression 62 
Human miR-125b Bmf human glioma cell 
decreased proliferation and enhanced 
the sensitivity to all-trans-retinoic 
acid (ATRA)-induced 
apoptosis.(promoted the late cell 
apoptosis) 
Down-regulation 62 
Mouse miR-125b Smo medulloblastoma (MBs) Inhibit Hedgehog (Hh) signaling. Over-expression 17 
Mouse miR-125b Gli1 undifferentiated granule 
cell progenitors (GCPs) 
delay growth arrest and 
differentiation Down-regulation 17 
Mouse miR-125b Gli1 undifferentiated granule 
cell progenitors (GCPs) 
To reduce the proliferation rate and 
to differentiate. Over-expression 17 
Human miR-125b Bcl-2 hepatocellular carcinoma (HCC) 
suppresses HCC cell 
proliferation and promotes apoptosis Over-expression 67 
 
Table: 1. Elucidation of miR-125a/b regulation in different cell types with the types of interaction and the target genes. 
Of all the published studies, we came across 
approximately 20% of papers [27, 29, 26, 
57, 7, 43] that are proved in computational 
approach by using following prediction 
algorithms like TargetScan [37], PicTar 
[47], miRBase [20] MicroCosm Target 
databases [20], miRanda [30], 30% proved 
experimentally [58, 36, 6, 16, 39, 13, 49, 56] 
and another approximately 50% proved by 
computational methods followed by 
experimental methods [24, 34, 55, 50, 18, 
66, 22, 32, 12, 41, 31, 52, 11, 65, 48, 62]. 
During our literature survey, we came across 
paper showing miRNA- target gene binding 
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site [9]. miRNA has more than 100 target 
genes [8]. We adopted the same method as 
we concentrated on single miRNA. To find 
out binding energy and miRNA- target gene 
binding first we downloaded miRNA-125 
from miRBase and all target gene sequences 
were stored in FASTA format. We used 
miRanda 3.3 with gap open penalty: -9.0, 
gap extend penalty: -4.0, score threshold: 
140.0, energy threshold: 1.0 kcal/mol, 
scaling parameter: 4.0. Query representing 
miR-125 and Ref representing target gene 
sequence name in Supplementary Table 2. 
After finding the results from miRanda of 
miRNA-125-binding to the target genes we 
found that based on the observation seed 
region if miRNA-125 in human, mouse and 
rat (Table 3). 
MiRNA Name Seed regions 
hsa-miR-125a-3p 5' CAGGUGA 3' 
mmu-miR-125a-3p 5' CAGGUGA 3' 
hsa-miR-125a-5p   5' CCCUGAGA 3' 
hsa-miR-125b-5p   5' CCCUGAGA 3' 
mmu-miR-125b-5p 5' CCCUGAGA 3' 
hsa-miR-125b-1-3p 5' CGGGUUA 3' 
mmu-miR-125b-1-3p 5' CGGGUUA 3' 
hsa-miR-125b-2-3p 5' CACAAGU 3' 
mmu-miR-125b-2-3p    5' CAAGUCA 3' 
Table: 3. showing miR-125a/b in Homo sapiens and Mus 
musculus with seed regions. 
During our analysis we found that some of 
the genes like Bak1, CDK6, PPP1CA, IGF2, 
DICER-1, BLIMP-1, and GLI1 are seen in 
human and mouse which are bound to 
miRNA-125. We performed MSA of seven 
genes to identify homology and also the 
region of miRNA-125 binding. We used 
multiple alignments from Geneious 5.6.4 
with default value as follow cost matrix: 
65% similarity (5.0/-4.0), gap open penalty 
12, and gap extension penalty 3, alignment 
type: global alignment with free end gaps. 
The results are shown in Figure 2. 
A)  
 
B)  
 
C)  
 
D)  
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E)  
 
F)  
 
G)  
 
H)  
 
I) 
 
 Fig: 2. Showing multiple pairwise alignment of target gene and illustrating identical sites (IS) and pairwise % identity (PI) for 
A,B,C,D and F respectively BAK1 (IS) 43 (49.4%), (PI) 58.8%, BLIMP1-153 (60.2%), 67.4%, IGF243 (50.0%), 63.3%, DICER-
148 (60.0%), 65.9%, PPP1CA69 (86.3%),88.5%, between Homo sapiens=hsa and Mus musculus=mmu. Pairwise sequence align 
and illustrating identical sites (IS) and pairwise % identity (PI) for E,G,H and I respective DICER1 75 (94.9%), 94.9%, GLI1 14 
(53.8%),53.8%, ST18 42 (52.5%),52.5% and CDK6 14 (66.7%),66.7% between Homo sapiens=hsa and Mus musculus=mmu. 
 
3.3 Over-expression of miRNA-125 
In the cell, improper expression of miRNA alters 
the regulatory network leading to abnormality in 
its functions that cause proliferation, production 
of more protein, signaling etc. and finally 
resulting in cancer. miRNA have a role in cancer 
due to deletion, amplification or chromosomal 
translocation region. In patients carrying the 
t(2;11)(p21;q23) translocation in 
myelodysplastic syndromes (MDS) and acute 
myeloid  leukemia (AML) have showed the 
over-expression of miR-125b (6 to 90-fold) than 
in healthy person which block the process of 
differentiation in monocytes  
 
 
and granulocytes [7]. In other case, over-
expression of miR-125b from 30 to 600-fold in 
B-acute lymphoid leukemia (ALL) patients due 
the translocation t (11;14)(q24;q32) [10]. Other 
studies show that due to distal losses of chr 11q 
and 21 contribute to the reduced expression of 
miR-125b that cause oral squamous cell 
carcinoma (OSCC) [25]. Over-expression of 
miR-125 in germinal centers (GC) phase of B 
cell, inhibit B cell differentiation into plasma 
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cells by targeting BLIMP-1 and IRF-4 
transcription factors [23]. 
 ETS2 and ERG are transcription factors of the 
family ETS are encoded on human chr 21. 
Similar arrangement in mouse on the chr 16 
which is homologous [3]. High level of ERG 
indicates the cause of AML and ALL [44, 2]. 
When both mRNAs, ETS2 and ERG high 
expression has been observed in AML patients 
with complex karyotypes and abnormal chr 21 
[3]. ERG is required for definitive hematoposis 
and for maintenance of proper platelets number 
in normal hematopoiesis [44]. Over-expression 
of ERG, ETS2 and FLI-1 phosphorylated 
STAT3 that activates JAK/STAT pathway from 
Gata1- knockdown cells finally result on 
megakaryocyte malignancies [59]. 
Megakaryopoies is favor in low levels of c-myb. 
Further the over-expression of ERG inhibits the 
expression of c-myb [15]. ERG cooperates with 
GATA1s [54]. GATA1 mutations cause myeloid 
leukemia of Downs’ syndrome (DS). DS face a 
500-fold increased risk for acute 
megakaryoblastic leukemia (AMKL) [51, 61, 
63]. GATA1 binding to RUNX1 has lead to 
active αIIb integrin megakaryocytic promoter 
element. Mutation in GATA1 due to deletion of 
sequence in transcription activation site leads to 
megakaryocytic Leukemia [61]. The truncated 
forms of GATA-1 lack RUNX1 which is 
significant in trisomy 21 [14]. Over-expression 
of miR-125b-2 cooperates with Gata1s mutation 
in fetal livers (FLs) progenitors [31]. miR-125b 
over-expression is associated with oncogenes 
like BCR-ABL fusion protein to promote 
leukemia [6]. 
chr 21 encodes four miRNAs (hsa-mir-99a; hsa-
let-7c; hsa-mir-125b-2 and hsa-mir-155). hsa-
mir-125b-2 cluster are upregulated in the 
ETV6/RUNX1 ALL, hsa-mir-155 expressed in 
all subtype of leukemia cells. Over-expression of 
miR-125b-2 inhibits the apoptosis and caspase 3 
activation in response to IL3 scarcity [19]. IL3 
promote cell survival through JAK/STAT 
pathway [45, 28, 40, 5]. Expression of miR-125b 
contributes to myeloid cell proliferation and 
promoting leukemogenesis by down-regulating 
CBFβ [39]. miR-125a expression down-
regualates proapoptotic protein Bak1 (40 - 50%) 
that reduce apoptosis in immature hematopoietic 
progenitors cells [65]. Over-expression of miR-
125b in pediatric acute promyelocytic leukemia 
(APL) inhibits Bak1 expression that reduces 
apoptosis and enhanced proliferation of 
leukemic cells [48].  
 
Fig: 3. Potential role of microRNA-125 overexpression 
in regulatory mechanisms. Mechanism of microRNA-125 
mediated gene regulation in different types. miRNA direct 
targeting the mRNA and regulating the expression of the 
target gene at post-transcriptional levels (mRNA 
degradation and inhibit translation). The over-expression of 
miRNA changes the specific function and lead to cancer 
(leukemia).  
 
[IV] CONCLUSION 
Our studies imply that miR-125 acts as an 
oncogene. All these reports from Figure 3 entail 
that miR-125 expression considerably causes 
different types of cancers mainly leukemia. The 
abnormality in its functions due to different 
types of genes and miRNA which is encoded on 
chr 21 leads to Downs’ syndrome, leukemia and 
other types of cancers. This might be important 
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factor in clinical therapeutics. In this paper, we 
studied deeply on miR-125 positive and negative 
regulation and find the binding energy of miR-
125 binding site with different target genes. 
Different pathways show that over-expression of 
miR-125 resulting in leukemia. 
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miRNA NAME  
REGION 
NUMBER 
ALIGNMENT 
TARGET 
GENE NAME BIND SITES BIND ENERGY 
hsa-miR-125a-5p 3002 to 3024 Align ARID3B 
 Query:      3' agUGUCCAAUUUCCCAGAGUCCCu 5' 
                  :||||  |:|  | ||||||| 
   Ref:      5' auGCAGGGGAGA-CGACUCAGGGa 3' 
 -24.680000 kCal/Mol 
hsa-miR-125a-5p 3736 to 3759 Align ARID3B 
 Query:      3' aguguccaauuucccAGAGUCCCu 5' 
                               |||||||| 
   Ref:      5' uggccaguaugucuuUCUCAGGGg 3' 
 -19.230000 kCal/Mol 
hsa-miR-125a-5p 2124 to 2147 Align ARID3B 
   Query:    3' aguguccaauuucccaGAGUCCCu 5' 
                                ||||||| 
   Ref:      5' cccagccaccucccagCUCAGGGc 3' 
 -15.850000 kCal/Mol 
hsa-miR-125a-5p 3162 to 3185 Align ARID3B 
   Query:    3' aguguccaauuucccaGAGUCCCu 5' 
                                ||||||| 
   Ref:      5' cacucagcauucccagCUCAGGGc 3' 
 -17.430000 kCal/Mol 
hsa-miR-125a-3p 639 to 659 Align ARID3B 
   Query:    3' ccGAGGGUUCUUGGAGUGGAca 5' 
                  ||:||||| :|||||||| 
   Ref:      5' ugCUUCCAAG-GCCUCACCUuc 3' 
 -31.740000 kCal/Mol 
hsa-miR-125a-3p 1160 to 1181 Align ARID3B 
   Query:    3' ccGAGGGUUCUUGGAGUGGACa 5' 
                  |||:: :|   |||||||| 
   Ref:      5' ccCUCUUUGGCUACUCACCUGc 3' 
 -21.680000 kCal/Mol 
hsa-miR-125a-3p 3843 to 3864 Align ARID3B 
   Query:    3' ccgaGGGUUCUUGGAGUGGACa 5' 
                    ||||:| | |||:|||| 
   Ref:      5' uuucCCCAGGCAGCUCGCCUGg 3' 
 -26.959999 kCal/Mol 
hsa-miR-125b-5p 1552 to 1573 Align BAK1 
   Query:    3' aguguUCAAUCCCAGAGUCCCu 5' 
                     ||||:|  |||||||| 
   Ref:      5' uuugcAGUUGGACUCUCAGGGa 3' 
 -24.700001 kCal/Mol 
hsa-miR-125b-5p 2054 to 2075 Align BAK1 
   Query:    3' agUGUUCAAUCCCAGAGUCCCu 5' 
                  |||:  ||||||||::||| 
   Ref:      5' gcACAGCCUAGGGUCUUGGGGg 3' 
 -33.259998 kCal/Mol 
mmu-miR-125b-5p 1477 to 1498 Align Bak1 
   Query:    3' aguguUCAAUCCCAGAGUCCCu 5' 
                     :| |:|  |||||||| 
   Ref:      5' uuggcGGCUGGACUCUCAGGGa 3' 
 -20.410000 kCal/Mol 
hsa-miR-125b-1-3p 2270 to 2290 Align BLIMP-1 
   Query:    3' ucGAGGGUUCUCGGAUUGGGCa 5' 
                  ||:  |||| :||:||||| 
   Ref:      5' ccCUUGGAAGA-UCUGACCCGa 3' 
 -22.270000 kCal/Mol 
hsa-miR-125b-5p 179 to 200 Align BLIMP-1 
   Query:    3' agUGUUCAAUCCCAGAGUCCCu 5' 
                  :||   |: |||:|||||| 
   Ref:      5' caGCACUGUGAGGUUUCAGGGa 3' 
 -26.350000 kCal/Mol 
hsa-miR-125b-5p 2459 to 2480 Align BLIMP-1 
   Query:    3' aguguucaaucccaGAGUCCCu 5' 
                              ||||||| 
   Ref:      5' aauggacuccucucCUCAGGGu 3' 
  -13.950000 kCal/Mol 
hsa-miR-125a-5p 177 to 200 Align BLIMP-1 
   Query:    3' aguguccaAUUUCCCAGAGUCCCu 5' 
                        |: : |||:|||||| 
   Ref:      5' uccagcacUGUGAGGUUUCAGGGa 3' 
 -24.480000 kCal/Mol 
hsa-miR-125a-5p 2457 to 2480 Align BLIMP-1 
   Query:    3' aguguccaauuucccaGAGUCCCu 5' 
                                ||||||| 
   Ref:      5' ggaauggacuccucucCUCAGGGu 3' 
 -14.890000 kCal/Mol 
hsa-miR-125a-3p 2215 to 2234 Align BLIMP-1 
   Query:    3' ccgaGGGUUCUUGGAGUGGACa 5' 
                    |:||||:  :||||||| 
   Ref:      5' uagcCUCAAGG--UUCACCUGa 3' 
 -24.940001 kCal/Mol 
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mmu-miR-125b-1-
3p 2467 to 2488 Align BLIMP-1 
   Query:    3' ucGAGGGUUCUCGGAUUGGGCa 5' 
                  ||:: :||: :||:||||| 
   Ref:      5' gcCUUUGGAGGAUCUGACCCGa 3' 
 -25.780001 kCal/Mol 
mmu-miR-125b-2-
3p 2819 to 2840 Align BLIMP-1 
   Query:    3' uccAGGGUUCUUGGACUGAACa 5' 
                   |:|: ||::: ||:|||| 
   Ref:      5' ugcUUCUUAGGGUAUGGCUUGg 3' 
 -17.730000 kCal/Mol 
mmu-miR-125b-5p 2948 to 2969 Align BLIMP-1 
   Query:    3' aguguucaaucccAGAGUCCCu 5' 
                             |||||||| 
   Ref:      5' aauguuaccaaaaUCUCAGGGc 3' 
 -15.070000 kCal/Mol 
mmu-miR-125b-5p 2657 to 2678 Align BLIMP-1 
   Query:    3' aguguucaaucccaGAGUCCCu 5' 
                              ||||||| 
   Ref:      5' aacggccuccucucCUCAGGGu 3' 
 -15.290000 kCal/Mol 
hsa-miR-125b-5p 2218 to 2238 Align BMF 
   Query:    3' agUGUUCAAUCCCAGAGUCCCu 5' 
                  ||||   | |  ||||||| 
   Ref:      5' ggACAA-AGAAGACCUCAGGGc 3' 
 -16.049999 kCal/Mol 
hsa-miR-125b-5p 2611 to 2632 Align BMF 
   Query:    3' agugUUCAAUCCCAGAGUCCCu 5' 
                    :| ||    |||||||| 
   Ref:      5' gucaGAAUUCUAUUCUCAGGGu 3' 
 -17.059999 kCal/Mol 
hsa-miR-125b-5p 1401 to 1422 Align BMF 
   Query:    3' aguguucaaucccaGAGUCCCu 5' 
                              ||||||| 
   Ref:      5' caccuccagcagacCUCAGGGa 3' 
 -16.809999 kCal/Mol 
hsa-miR-125a-5p 2609 to 2632 Align BMF 
   Query:    3' aguguccaauuucccAGAGUCCCu 5' 
                               |||||||| 
   Ref:      5' uggucagaauucuauUCUCAGGGu 3' 
 -17.469999 kCal/Mol 
hsa-miR-125a-5p 1399 to 1422 Align BMF 
   Query:    3' aguguccaauuucccaGAGUCCCu 5' 
                                ||||||| 
   Ref:      5' gccaccuccagcagacCUCAGGGa 3' 
 -17.440001 kCal/Mol 
hsa-miR-125a-3p 4224 to 4245 Align BMF 
   Query:    3' ccgagggUUCUUGGAGUGGACa 5' 
                       |||:: |||||||| 
   Ref:      5' uagcaggAAGGGGCUCACCUGu 3' 
 -23.709999 kCal/Mol 
hsa-miR-125b-5p 1706 to 1727 Align BMPR1B 
   Query:    3' aguguucaaucccAGAGUCCCu 5' 
                             |||||||| 
   Ref:      5' uucagaccucaccUCUCAGGGa 3' 
 -17.450001 kCal/Mol 
hsa-miR-125b-5p 234 to 255 Align CBFB 
   Query:    3' aguguucaaucCCAGAGUCCCu 5' 
                           || ||||||| 
   Ref:      5' ccggccggcgcGGCCUCAGGGc 3' 
 -18.059999 kCal/Mol 
hsa-miR-125a-5p 150 to 174 Align  CCL21 
   Query:    3' agUGUC-CAAUUUCCCAGAGUCCcu 5' 
                  :||| | |::|||| |||||| 
   Ref:      5' agGCAGUGAUGGAGGGGCUCAGGac 3' 
 -26.190001 kCal/Mol 
hsa-miR-125a-3p 378 to 399 Align CCL4 
   Query:    3' ccGAGGGUUCUUGGAGUGGACa 5' 
                  ||:| ::|||  ||||||| 
   Ref:      5' guCUUCAGGGAAGGUCACCUGa 3' 
 -21.870001 kCal/Mol 
hsa-miR-125a-3p 960 to 984 Align CDC25A 
   Query:    3' ccGAGGGUUCUUGG---AGUGGACa 5' 
                  ||::: | | ||   ||||||| 
   Ref:      5' cuCUUUUUACACCCCAGUCACCUGu 3' 
 -20.400000 kCal/Mol 
hsa-miR-125a-3p 467 to 489 Align CDC25A 
   Query:    3' ccGAGGGUUCUUGG-AGUGGACa 5' 
                  | || ::|:||: ||:|||| 
   Ref:      5' gcCGCCGGGGGACUGUCGCCUGu 3' 
 -26.190001 kCal/Mol 
hsa-miR-125b-5p 1 to 9 Align CDC25C 
   Query:    3' aguguucaaucccaGAGUCCCu 5' 
                              ||||||| 
   Ref:      5' -------------gCUCAGGGa 3' 
 -16.440001 kCal/Mol 
hsa-miR-125a-5p 10856 to 10879 Align CDK6 
   Query:    3' aguGUCCAAUUUCCCAGAGUCCcu 5' 
                   :| |  ||| || |||||| 
   Ref:      5' cucUAAGAAAAAUGGCCUCAGGua 3' 
 -12.730000 kCal/Mol 
hsa-miR-125a-3p 7809 to 7825 Align CDK6 
   Query:    3' ccGAGGGUUCUUGGAGUGGACa 5' 
                  ||||||     |||||||| 
   Ref:      5' gcCUCCCA-----CUCACCUGc 3' 
 -24.629999 kCal/Mol 
hsa-miR-125a-3p 8878 to 8899 Align  CDK6 
   Query:    3' ccGAGGGUUCUUGGAGUGGACa 5' 
                  | ||||:||||  |||||| 
   Ref:      5' uaCCCCCAGGAACAGCACCUGa 3' 
 -30.760000 kCal/Mol 
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hsa-miR-125a-3p 2923 to 2944 Align CDK6 
   Query:    3' ccGAGGGUUCUUGGAGUGGACa 5' 
                  :|::||: : |:|:||||| 
   Ref:      5' uaUUUUCAGUGUCUUUACCUGa 3' 
 -19.870001 kCal/Mol 
mmu-miR-125a-3p 967 to 987 Align CDK6 
   Query:    3' ccgaGGGUUCUUGGAGUGGACa 5' 
                    ||::| | :|||||||| 
   Ref:      5' acaaCCUGA-ACUCUCACCUGc 3' 
 -24.030001 kCal/Mol 
hsa-miR-125a-5p 1340 to 1363 Align CDKN2A 
   Query:    3' aguguccaAUUUCCCAGAGUCCCu 5' 
                        ||::|   ||||||| 
   Ref:      5' uugugaacUAGGGAAGCUCAGGGg 3' 
 -23.110001 kCal/Mol 
mmu-miR-125b-5p 8063 to 8084 Align DICER-1 
   Query:    3' agUGUUCAAUCCCAGAGUCCCu 5' 
                  ||||   ||  |:|||||| 
   Ref:      5' caACAAAAGAGCCUUUCAGGGa 3' 
 -18.860001 kCal/Mol 
mmu-miR-125b-5p 436 to 457 Align DICER-1 
   Query:    3' aguguucaauccCAGAGUCCCu 5' 
                            | ||||||| 
   Ref:      5' ugcuugaacacuGGCUCAGGGa 3' 
 -19.320000 kCal/Mol 
mmu-miR-125b-1-
3p 2196 to 2217 Align DICER-1 
   Query:    3' ucGAGGGUUCUCGGAUUGGGCa 5' 
                  |||||||  |:  |||||| 
   Ref:      5' agCUCCCAAAUGUAGAACCCGa 3' 
 -30.410000 kCal/Mol 
mmu-miR-125b-2-
3p 5420 to 5437 Align  DICER-1 
   Query:    3' ucCAGGGUUCUUGGACUGAACa 5' 
                  |||:::|    |||||||| 
   Ref:      5' ggGUCUUGA----CUGACUUGc 3' 
 -20.809999 kCal/Mol 
mmu-miR-125b-2-
3p 686 to 705 Align DICER-1 
   Query:    3' ucCAGGGUUCUUGGACUGAACa 5' 
                  ||:|: |  |  ||||||| 
   Ref:      5' agGUUCUCAUUA--UGACUUGc 3' 
 -18.379999 kCal/Mol 
mmu-miR-125b-2-
3p 9542 to 9563 Align DICER-1 
   Query:    3' ucCAGGGUUCUUGGACUGAACa 5' 
                  | ||: ||||::|| |||| 
   Ref:      5' auGGCCUCAGAAUUUGCCUUGg 3' 
 -19.620001 kCal/Mol 
hsa-miR-125b-1-3p 1992 to 2013 Align DICER-1 
   Query:    3' ucGAGGGUUCUCGGAUUGGGCa 5' 
                  ||||:||  ||  |||||| 
   Ref:      5' agCUCCUAAAUGCAGAACCCGa 3' 
 -30.240000 kCal/Mol 
hsa-miR-125b-1-3p 5471 to 5490 Align DICER-1 
   Query:    3' ucGAGGGUUCUCGGAUUGGGCa 5' 
                  || |||| | ::||:|||| 
   Ref:      5' aaCUGCCAA-A-UUUAGCCCGg 3' 
 -21.670000 kCal/Mol 
hsa-miR-125b-5p 232 to 253 Align DICER-1 
   Query:    3' aguguucaauccCAGAGUCCCu 5' 
                            | ||||||| 
   Ref:      5' uguuuaaacacuGGCUCAGGGa 3' 
 -19.320000 kCal/Mol 
hsa-miR-125b-2-3p 4597 to 4618 Align EGFR 
   Query:    3' caggguucUCGGACUGAACAcu 5' 
                        || ||||||||| 
   Ref:      5' ugagcguuAGACUGACUUGUuu 3' 
 -17.200001 kCal/Mol 
mmu-miR-125b-2-
3p 4835 to 4856 Align ERBB2 
   Query:    3' uccaggguucuUGGACUGAACa 5' 
                           |: ||||||| 
   Ref:      5' agagcauugccAUGUGACUUGu 3' 
 -13.920000 kCal/Mol 
 hsa-miR-125a-3p 3413 to 3434 Align ERBB3 
   Query:    3' ccGAGGGUUCUUGGAGUGGACa 5' 
                  ||:::|||  | |||:||| 
   Ref:      5' gcCUUUUAAGUCCAUCAUCUGg 3' 
 -21.350000 kCal/Mol 
hsa-miR-125a-5p 4144 to 4167 Align ERBB3 
   Query:    3' agUGUCCAAUUUCCCAGAGUCCCu 5' 
                  | || | |:||  |:|||||| 
   Ref:      5' gaAGAGAUGAGAGCUUUUCAGGGg 3' 
 -18.629999 kCal/Mol 
hsa-miR-125a-5p 4308 to 4331 Align ERBB3 
   Query:    3' aguguccaauuuCCCAGAGUCCCu 5' 
                            ||  ||||||| 
   Ref:      5' ccugcucccuguGGCACUCAGGGa 3' 
 -17.340000 kCal/Mol 
hsa-miR-125b-2-3p 2753 to 2773 Align GLI1 
   Query:    3' caGGGUUCUCGGACUGAACACu 5' 
                  |:|||| ||:  :|||||| 
   Ref:      5' agCUCAAG-GCUCAGCUUGUGu 3' 
 -22.080000 kCal/Mol 
mmu-miR-125b-5p 807 to 828 Align GLI1 
   Query:    3' aguGUUCAAUCCCAGAGUCCCu 5' 
                   :| || |||||| ||||| 
   Ref:      5' cuuUAUGUCAGGGUCCCAGGGu 3' 
 -23.280001 kCal/Mol 
hsa-miR-125a-3p 4974 to 4995 Align IGF2 
   Query:    3' ccgaggguuCUUGGAGUGGACa 5' 
                         |||: ||||||| 
   Ref:      5' ccaaacacuGAAUGUCACCUGu 3' 
 -19.850000 kCal/Mol 
hsa-miR-125a-3p 4942 to 4962 Align IGF2 
   Query:    3' ccGAGGGUUCUUGGAGUGGACa 5' 
                  ||||:  |  | ||||||| 
   Ref:      5' ccCUCCUCUG-CCAUCACCUGa 3' 
 -22.629999 kCal/Mol 
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mmu-miR-125a-3p 3524 to 3545 Align IGF2 
  Query:    3' ccgaggguucuUGGAGUGGACa 5' 
                           |: ||||||| 
  Ref:      5' ucgaacgccauAUGUCACCUGu 3' 
 -19.240000 kCal/Mol 
mmu-miR-125a-3p 1390 to 1410 Align  IGF2 
   Query:    3' ccgAGGGUUCUUGGAGUGGAca 5' 
                   |||||| ||:|||||:| 
   Ref:      5' cagUCCCAA-AAUCUCACUUuu 3' 
 -21.799999 kCal/Mol 
mmu-miR-125a-5p 3315 to 3338 Align  IGF2 
 Query:      3' agUGUCCAAUUUCCCAGAGUCCCu 5' 
                  :::|| |::: | |:|||||| 
   Ref:      5' ucGUGGGAUGGGUGCUUUCAGGGg 3' 
 -26.150000 kCal/Mol 
hsa-miR-125b-5p 612 to 633 Align IL16 
   Query:    3' agUGUUCAAUCCCA-GAGUCCCu 5' 
                  :|||| ||  || |||:||| 
   Ref:      5' gaGCAAG-UACUGUCCUCGGGGu 3' 
 -20.370001 kCal/Mol 
mmu-miR-125b-2-
3p 2452 to 2474 Align IRF4 
   Query:    3' uccAGGG-UUCUUGGACUGAACa 5' 
                   |||| ||||::|| ||||| 
   Ref:      5' gaaUCCCAAAGAGUCUCACUUGc 3' 
 -23.000000 kCal/Mol 
hsa-miR-125b-5p 2057 to 2078 Align IRF-4 
   Query:    3' aguguucaaucccAGAGUCCCu 5' 
                             |||||||| 
   Ref:      5' ugucugugccauuUCUCAGGGa 3' 
 -16.790001 kCal/Mol 
hsa-miR-125b-2-3p 735 to 755 Align IRF-4 
   Query:    3' caggGUUCUCGGACUGAACACu 5' 
                    |||| |||  :|||||| 
   Ref:      5' cuggCAAG-GCCCAGCUUGUGa 3' 
 -22.209999 kCal/Mol 
hsa-miR-125b-2-3p 2596 to 2617 Align ITCH 
   Query:    3' caGGGUUCUCGGACUGAACAcu 5' 
                  ||||: ||||  |||||| 
   Ref:      5' uaCCCAGAAGCCAUACUUGUuu 3' 
 -22.889999 kCal/Mol 
hsa-miR-125b-5p 5923 to 5944 Align KLF13 
   Query:    3' aguguucAAUCCCAGAGUCCCu 5' 
                       ||| || ||||||| 
   Ref:      5' agcuuucUUAAGGCCUCAGGGu 3' 
  -17.750000 kCal/Mol 
hsa-miR-125b-5p 1433 to 1454 Align KLF13 
   Query:    3' aguguucaaucccAGAGUCCCu 5' 
                             |||||||| 
   Ref:      5' guugaacccccuuUCUCAGGGa 3' 
 -16.520000 kCal/Mol 
hsa-miR-125b-5p 3463 to 3483 Align KLF13 
   Query:    3' agUGUUCAAUCCCAGAGUCCcu 5' 
                  |||  |||  |||||||| 
   Ref:      5' auACAUUUUA-UGUCUCAGGaa 3' 
 -17.230000 kCal/Mol 
hsa-miR-125b-2-3p 2653 to 2674 Align KLF13 
   Query:    3' caggguuCUCGGACUGAACACu 5' 
                       || || |:|||||| 
   Ref:      5' gaguguuGACCCAGGCUUGUGg 3' 
 -18.150000 kCal/Mol 
hsa-miR-125b-5p 1531 to 1552 Align LIN28A 
   Query:    3' aguguucaaucccAGAGUCCCu 5' 
                             |||||||| 
   Ref:      5' gguacaugagcaaUCUCAGGGa 3' 
 -21.000000 kCal/Mol 
hsa-miR-125b-5p 3864 to 3885 Align MCL1 
   Query:    3' aguguucaaucccAGAGUCCCu 5' 
                             |||||||| 
   Ref:      5' ugucuuacgcuucUCUCAGGGa 3' 
 -17.770000 kCal/Mol 
hum-miR-125b-5p 936 to 957 Align MLF2 
   Query:    3' aguguucAAUCCCAGAGUCCCu 5' 
                       | :||||||||||| 
   Ref:      5' cucucccUGGGGGUCUCAGGGa 3' 
 -28.330000 kCal/Mol 
hum-miR-125b-5p 697 to 718 Align MLF2 
   Query:    3' agUGUUCAAUCCCAGAGUCCCu 5' 
                  :|:: ||: |  ||||||| 
   Ref:      5' cgGCGGCUUGAGUCCUCAGGGg 3' 
 -19.400000 kCal/Mol 
hsa-miR-125a-3p 1067 to 1088 Align MLF2 
   Query:    3' ccGAGGGUUCUUGGAGUGGAca 5' 
                  ||:| ||   |||||||| 
   Ref:      5' auCUUCAAACCCCCUCACCUuu 3' 
 -18.980000 kCal/Mol 
hsa-miR-125a-5p 934 to 957 Align MLF2 
   Query:    3' aguguccaauUUCCCAGAGUCCCu 5' 
                          ::||||||||||| 
   Ref:      5' accucucccuGGGGGUCUCAGGGa 3' 
   -28.700001 kCal/Mol 
hsa-miR-125b-1-3p 1041 to 1061 Align NFKB1 
   Query:    3' ucgagggUUCUCGGAUUGGGCa 5' 
                       ||||| ||||:||| 
   Ref:      5' cgggaaaAAGAG-CUAAUCCGc 3' 
 -19.049999 kCal/Mol 
hsa-miR-125b-5p 3624 to 3645 Align NOTCH1 
   Query:    3' aguguucaaUCCCAGAGUCCCu 5' 
                         :||  ||||||| 
   Ref:      5' cugcccacgGGGCACUCAGGGu 3' 
 -22.290001 kCal/Mol 
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hsa-miR-125b-5p 9061 to 9082 Align NOTCH1 
   Query:    3' aguguucaaucccaGAGUCCCu 5' 
                              ||||||| 
   Ref:      5' ugccgccugcacucCUCAGGGc 3' 
 -15.200000 kCal/Mol 
hsa-miR-125b-1-3p 409 to 430 Align NOTCH1 
   Query:    3' ucgAGGGUUCUCGGAUUGGGCa 5' 
                   | |||: || ||:||||| 
   Ref:      5' ucgUGCCAGCAGGCUGACCCGu 3' 
  -26.410000 kCal/Mol 
hsa-miR-125b-1-3p 166 to 187 Align NOTCH1 
   Query:    3' ucgAGGGUUCUCGGAUUGGGCa 5' 
                   | |||:|| || |||||| 
   Ref:      5' cgaUGCCAGGACCCCAACCCGu 3' 
 -25.600000 kCal/Mol 
hsa-miR-125b-1-3p 5926 to 5946 Align NOTCH1 
   Query:    3' ucGAGGGUUCUCGGAUUGGGCa 5' 
                  ||:|| ||| |||:|:||| 
   Ref:      5' guCUUCC-AGAUCCUGAUCCGg 3' 
 -27.559999 kCal/Mol 
hsa-miR-125b-5p 1418 to 1439 Align PPP1CA 
   Query:    3' aguguucaaucCCAGAGUCCCu 5' 
                           || ||||||| 
   Ref:      5' cagccgugcuuGGCCUCAGGGc 3' 
 -17.920000 kCal/Mol 
hsa-miR-125b-5p 1372 to 1392 Align PPP1CA 
   Query:    3' agugUUCAAUCCCAGAGUCCCu 5' 
                    |:| |:  | ||||||| 
   Ref:      5' gccgAGGCUGCAG-CUCAGGGc 3' 
 -19.910000 kCal/Mol 
mmu-miR-125b-5p 1241 to 1262 Align PPP1CA 
   Query:    3' aguGUUCAAUCCCAGAGUCCCu 5' 
                   ||||   |   ||||||| 
   Ref:      5' ggcCAAGGCUGCAGCUCAGGGc 3' 
 -19.969999 kCal/Mol 
hsa-miR-125b-2-3p 1977 to 1998 Align PPP2CA 
   Query:    3' caggguucucggacUGAACACu 5' 
                              ||||||| 
   Ref:      5' guuuuucauaauaaACUUGUGa 3' 
 -12.400000 kCal/Mol 
rno-mir-125a 1023 to 1046 Align PTGES2 
   Query:    3' aguguccaAUUUCCCAGAGUCCCu 5' 
                        ||   |||:|||||| 
   Ref:      5' ucaagaccUACCUGGUUUCAGGGc 3' 
 -19.209999 kCal/Mol 
mmu-miR-125b-1-
3p 275 to 296 Align PUMA 
   Query:    3' ucgagggUUCUCGGAUUGGGCa 5' 
                       :||:|:|||:|||| 
   Ref:      5' gcccguaGAGGGUCUAGCCCGc 3' 
 -31.180000 kCal/Mol 
hsa-miR-125b-2-3p 901 to 921 Align RAF1 
   Query:    3' caGGGUUCUCGGACUGAACACu 5' 
                  ::|:|  |:| |||||||| 
   Ref:      5' auUUCGA-UGUCAGACUUGUGg 3' 
 -21.180000 kCal/Mol 
hsa-miR-125b-5p 1760 to 1780 Align RAF1 
   Query:    3' aguguucaaUCCCAGAGUCCCu 5' 
                         | || ||||||| 
   Ref:      5' gcccggcagACGG-CUCAGGGa 3' 
 -18.910000 kCal/Mol 
hsa-miR-125a-5p 1758 to 1780 Align RAF1 
   Query:    3' aguguccaaUUUCCCAGAGUCCCu 5' 
                         |:| || ||||||| 
   Ref:      5' uugcccggcAGACGG-CUCAGGGa 3' 
 -20.709999 kCal/Mol 
hsa-miR-125a-5p 2987 to 3010 Align RAF1 
   Query:    3' aguguccaauuucccAGAGUCCCu 5' 
                               |||||||| 
   Ref:      5' uccgcaucucagcccUCUCAGGGa 3' 
 -19.610001 kCal/Mol 
rno-miR-125b-5p 1649 to 1670 Align Slc35c2 
   Query:    3' agUGUUCAAUCCCAGAGUCCcu 5' 
                  :::|| |||  ||||||| 
   Ref:      5' agGUGAGGUAGUUUCUCAGGuu 3' 
-15.490000 kCal/Mol 
rno-mir-125a 1811 to 1834 Align Slc35c2 
   Query:    3' agugUCCAAUUUCCCAGAGUCCCu 5' 
                    ||| |||||||||| :||| 
   Ref:      5' ucugAGGAUAAAGGGUCUGGGGGu 3' 
 -30.920000 kCal/Mol 
mmu-miR-125b-5p 453 to 473 Align ST18 
   Query:    3' aguguucaaUCCCAGAGUCCCu 5' 
                         || | ||||||| 
   Ref:      5' ucugaucccAGAG-CUCAGGGu 3' 
 -17.350000 kCal/Mol 
hsa-miR-125b-5p 167 to 188 Align  ST18 
   Query:    3' agUGUUCAAUCCCAGAGUCCCu 5' 
                  || :  |: |  ||||||| 
   Ref:      5' uaACUGAAUGUGACCUCAGGGg 3' 
 -15.120000 kCal/Mol 
hsa-miR-125b-5p 3954 to 3973 Align STAT3 
   Query:    3' aguGUUCAAUCCCAGAGUCCCu 5' 
                   | :|||: |  ||||||| 
   Ref:      5' uguCUGGUUGAG--CUCAGGGa 3' 
 -19.530001 kCal/Mol 
hsa-miR-125b-5p 2220 to 2241 Align TP53 
   Query:    3' agUGUUCAAUCCCAGAGUCCCu 5' 
                  ||  |||     ||||||| 
   Ref:      5' agACUUGUUUUAUGCUCAGGGu 3' 
  -18.690001 kCal/Mol 
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Supplementary Table: 2. Prediction of miRNA binding site with target genes by using miRanda algorithm. The Table showing 
miR-125–binding site with target mRNA and binding energy query representing miR-125, ref representing sequence of target 
mRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
hsa-miR-125b-5p 1526 to 1545 Align TP53INP1 
   Query:    3' agUGUUCAAUCCCAGAGUCCCu 5' 
                  | || |||   |||||||| 
   Ref:      5' caAAAAUUUA--UUCUCAGGGu 3' 
 -15.010000 kCal/Mol 
hsa-miR-125a-5p 1522 to 1545 Align TP53INP1 
   Query:    3' aguguccaauuucccAGAGUCCCu 5' 
                               |||||||| 
   Ref:      5' caagcaaaaauuuauUCUCAGGGu 3' 
 -15.010000 kCal/Mol 
